# Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

> **NCT00837824** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 20 (actual)

## Conditions studied

- Fabry Disease
- Chronic Kidney Disease, Stage IV (Severe)

## Interventions

- **BIOLOGICAL:** Fabrazyme (agalsidase beta)
- **BIOLOGICAL:** Fabrazyme (agalsidase beta)

## Key facts

- **NCT ID:** NCT00837824
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-12
- **Primary completion:** 2003-08
- **Final completion:** 2003-08
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** The trial was terminated early due to inadequate study design.
- **Last updated:** 2015-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00837824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00837824, "Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00837824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*